
Sparsentan Provides Better Proteinuria Reduction in FSGS
BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental glomerulosclerosis (FSGS) compared with the angiotensin II receptor …